Sucampo Pharmaceuticals, Inc., a Bio Pharma company based in Bethesda, MD, focuses on the development and commercialization of drugs based on prostones, a class of novel endogenous bio-lipids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals' first product, AMITIZA(R) (lubiprostone), received marketing approval from the FDA in January 2006. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.

Contact Information

4520 East-West Highway
Suite 300
Bethesda, MD 20814

tel: 301-961-3400
fax: 301-961-3440


Investor Relations



Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $476.1M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.